117 related articles for article (PubMed ID: 38315518)
1. A bioconvergence study on platinum-free concurrent chemoradiotherapy for the treatment of HPV-negative head and neck carcinoma.
Gonnelli A; Sarogni P; Giannini N; Linsalata S; Di Martino F; Zamborlin A; Frusca V; Ermini ML; Puccini P; Voliani V; Paiar F
Artif Cells Nanomed Biotechnol; 2024 Dec; 52(1):122-129. PubMed ID: 38315518
[TBL] [Abstract][Full Text] [Related]
2. Disease outcome and associated factors after definitive platinum based chemoradiotherapy for advanced stage HPV-negative head and neck cancer.
de Roest RH; van der Heijden M; Wesseling FWR; de Ruiter EJ; Heymans MW; Terhaard C; Vergeer MR; Buter J; Devriese LA; de Boer JP; Navran A; Hoeben A; Vens C; van den Brekel M; Brakenhoff RH; Leemans CR; Hoebers F
Radiother Oncol; 2022 Oct; 175():112-121. PubMed ID: 35973619
[TBL] [Abstract][Full Text] [Related]
3. Evolving role of novel radiosensitizers and immune checkpoint inhibitors in (chemo)radiotherapy of locally advanced head and neck squamous cell carcinoma.
Ngamphaiboon N; Chairoungdua A; Dajsakdipon T; Jiarpinitnun C
Oral Oncol; 2023 Oct; 145():106520. PubMed ID: 37467684
[TBL] [Abstract][Full Text] [Related]
4. Concurrent weekly cisplatin and simultaneous integrated boost intensity-modulated radiotherapy of locally advanced squamous cell carcinoma of the head and neck.
Dubinský P; Jeremic B; Švajdová M; Barilíková G; Matula P; Nadzonová D; Vojtek V
Klin Onkol; 2022; 35(4):307-314. PubMed ID: 35989088
[TBL] [Abstract][Full Text] [Related]
5. Hybrid nano-architectures loaded with metal complexes for the co-chemotherapy of head and neck carcinomas.
Santi M; Frusca V; Ermini ML; Mapanao AK; Sarogni P; Gonnelli A; Giannini N; Zamborlin A; Biancalana L; Marchetti F; Voliani V
J Mater Chem B; 2023 Jan; 11(2):325-334. PubMed ID: 36484416
[TBL] [Abstract][Full Text] [Related]
6. Preclinical trial comparing radiotherapy alone versus standard radiochemotherapy in three human papilloma virus (HPV) negative and three HPV-positive head and neck squamous cell carcinoma (HNSCC) xenograft tumour models.
Valentini C; Ebert N; Koi L; Pfeifer M; Löck S; Erdmann C; Krause M; Baumann M
Radiother Oncol; 2023 Jun; 183():109546. PubMed ID: 36813172
[TBL] [Abstract][Full Text] [Related]
7. Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13-01).
Lee YG; Kang EJ; Keam B; Choi JH; Kim JS; Park KU; Lee KE; Kwon JH; Lee KW; Kim MK; Ahn HK; Shin SH; Kim HR; Kim SB; Yun HJ
BMC Cancer; 2020 Aug; 20(1):813. PubMed ID: 32854649
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001).
Prawira A; Brana-Garcia I; Spreafico A; Hope A; Waldron J; Razak AR; Chen EX; Jang R; O'Sullivan B; Giuliani M; Bayley A; Cho J; Wang L; Perez-Ordonez B; Weinreb I; Siu LL; Hansen AR
Invest New Drugs; 2016 Oct; 34(5):575-83. PubMed ID: 27289242
[TBL] [Abstract][Full Text] [Related]
9. Novel approach of prophylactic radiation to reduce toxicities comparing 2-step40 with 56-Gy simultaneous integrated boost intensity-modulated radiation therapy for locally advanced squamous cell carcinoma of the head and neck, an intergroup phase III trial (JCOG1912, NEW BRIDGE).
Yokota T; Zenda S; Kodaira T; Kiyota N; Fujimoto Y; Wasano K; Takahashi R; Mizowaki T; Homma A; Sasaki K; Machida R; Sekino Y; Fukuda H; ;
BMC Cancer; 2023 Nov; 23(1):1068. PubMed ID: 37932681
[TBL] [Abstract][Full Text] [Related]
10. Radiosensitization approaches for HPV-positive and HPV-negative head and neck squamous carcinomas.
Dok R; Bamps M; Glorieux M; Zhao P; Sablina A; Nuyts S
Int J Cancer; 2020 Feb; 146(4):1075-1085. PubMed ID: 31283004
[TBL] [Abstract][Full Text] [Related]
11. Clinical decision pathway and management of locally advanced head and neck squamous cell carcinoma: A multidisciplinary consensus in Asia-Pacific.
Guo Y; Nakashima T; Cho BC; Lim DW; Yang MH; Lou PJ; Corry J; Lin JC; Zhu GP; Kim KH; Zhang B; Li Z; Hong RL; Ng JYS; Tan EM; Liu YP; Stylianou C; Spiteri C; Porceddu S
Oral Oncol; 2024 Jan; 148():106657. PubMed ID: 38101313
[TBL] [Abstract][Full Text] [Related]
12. Concurrent chemoradiotherapy with cisplatin given once-a-week versus every-three weekly in head and neck squamous cell carcinoma: Non-inferior, equivalent, or superior?
Gupta T; Kannan S; Ghosh-Laskar S; Agarwal JP
Oral Oncol; 2022 Nov; 134():106130. PubMed ID: 36162191
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of docetaxel, cisplatin, and concurrent radiation followed by platinum-based adjuvant chemotherapy for technically unresectable, locally advanced head and neck squamous cell carcinoma.
Nakahara S; Takenaka Y; Ogawa K; Nishiike S; Yamamoto Y; Seo Y; Isohashi F; Suzuki O; Yoshioka Y; Sumida I; Yoshii T; Tomiyama Y; Inohara H
Int J Clin Oncol; 2016 Dec; 21(6):1030-1037. PubMed ID: 27306220
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine-Based Chemoradiation in the Treatment of Locally Advanced Head and Neck Cancer: Systematic Review of Literature and Meta-Analysis.
Vanderveken OM; Szturz P; Specenier P; Merlano MC; Benasso M; Van Gestel D; Wouters K; Van Laer C; Van den Weyngaert D; Peeters M; Vermorken J
Oncologist; 2016 Jan; 21(1):59-71. PubMed ID: 26712958
[TBL] [Abstract][Full Text] [Related]
15. Palbociclib-based high-throughput combination drug screening identifies synergistic therapeutic options in HPV-negative head and neck squamous cell carcinoma.
Gu Z; Shi C; Li J; Han Y; Sun B; Zhang W; Wu J; Zhou G; Ye W; Li J; Zhang Z; Zhou R
BMC Med; 2022 May; 20(1):175. PubMed ID: 35546399
[TBL] [Abstract][Full Text] [Related]
16. Loco-regional radiosensitizing nanoparticles-in-gel augments head and neck cancer chemoradiotherapy.
Bhardwaj P; Gota V; Vishwakarma K; Pai V; Chaudhari P; Mohanty B; Thorat R; Yadav S; Gurjar M; Goda JS; Banerjee R
J Control Release; 2022 Mar; 343():288-302. PubMed ID: 35101477
[TBL] [Abstract][Full Text] [Related]
17. A prospective phase II randomized study of docetaxel combined with lobaplatin versus TPF regimen induction chemotherapy followed by concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma.
Zhang M; Chen Y; Wu W; Jin F; Li Y; Long J; Luo X; Gong X; Chen X; Liu L; Tang H; Wang Z
J Cancer Res Clin Oncol; 2023 Dec; 149(20):18081-18091. PubMed ID: 37985501
[TBL] [Abstract][Full Text] [Related]
18. nab-Paclitaxel-based induction chemotherapy followed by cisplatin and radiation therapy for human papillomavirus-unrelated head and neck squamous-cell carcinoma.
Johnson KCC; Ley J; Oppelt P; Lu J; Gay HA; Daly M; Jackson R; Rich J; Pipkorn P; Paniello RC; Zevallos J; Thorstad W; Adkins DR
Med Oncol; 2019 Oct; 36(11):93. PubMed ID: 31595355
[TBL] [Abstract][Full Text] [Related]
19. Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC): A meta-analysis of randomized trials.
Budach W; Bölke E; Kammers K; Gerber PA; Orth K; Gripp S; Matuschek C
Radiother Oncol; 2016 Feb; 118(2):238-43. PubMed ID: 26589131
[TBL] [Abstract][Full Text] [Related]
20. Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.
Li L; Chen L; Yan L; Guo Y; Li F; Fan M; Lan M; Lai X; Zhou J; Huang Y; Xu P; Lang J; Feng M
Radiat Oncol; 2023 Jul; 18(1):109. PubMed ID: 37403098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
